Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...

OpenAI CEO Sam Altman surprised the tech world on Thursday with the launch of Operator, his company’s first AI agent that can ...

We saw several innovative uses of AI in the past week, and a bad slip-up in news sharing. A quick round-up: ...

Sam Altman, the CEO of OpenAI, is backing a groundbreaking initiative aimed at extending human lifespan by a decade through ...

The Financial Times today cited sources as saying that OpenAI Chief Executive Sam Altman is participating in the investment. He previously provided the initial $180 million funding round that helped ...

Disease-reversal startup Retro Biosciences is aiming for a $1 billion funding round, a spokesperson for the company confirmed ...

Up-and-coming country music star, Willow Avalon, makes her television debut on 'The Late Show with Stephen Colbert.' ...

What's trending in Bay Area business news this Friday morning: Twilio, EA Sports, Headlands Brewing, GameOn, 345 California, Retro Biosciences and more.

The pandemic saw a flurry of investment in biotech startups but the past three years have seen shrinking investments in the ...

Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...

The groundbreaking partnership focuses on leveraging AI to unlock advancements in cellular regeneration and anti-ageing ...

$540 $319 for your first year Make up your own mind. Build robust opinions on the FT's trusted journalism. Offer available until 27 February 2025. Then $75 per month. Complete digital access to ...